PharmAla Introduces MDMA Clinical Trial Tool for Researchers
Friday, August 23, 2024
PharmAla Biotech Holdings Inc., a biotechnology company specializing in the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives within the MDXX class, is excited to announce the release of a new tool designed to assist researchers. This tool provides qualified researchers with direct access to the company's Chemistry, Manufacturing, and Control (CMC) data, along with its investigator’s brochure.
“Recently, we’ve experienced a significant surge in requests for research materials related to MDMA. The FDA’s decision on the Lykos New Drug Application for MDMA has sparked increased interest among clinical researchers seeking information about our products. It's clear that MDMA continues to be a focal point for the global research community,” stated Nicholas Kadysh, CEO of PharmAla Biotech. “Building on the success of our prescriber’s portal in Canada, we’re now extending this new tool to the global clinical research community. We believe it will streamline the grant application process and demonstrate PharmAla’s commitment to regulatory transparency and excellence.”
The new tool, accessible at https://pharmala.ca/clinical-trials, allows researchers to directly review drug product quality information, simplifying the application process for MDMA clinical trials. PharmAla anticipates that this tool will bolster its sales pipeline as more researchers worldwide adopt LaNeo MDMA for their clinical studies.
CFO Transition
In addition, PharmAla Biotech is pleased to announce the appointment of Mr. William Avery, CPA, CA, as Chief Financial Officer, effective October 1st. Mr. Avery has been providing financial advisory services to PharmAla Biotech for over a month and brings a wealth of experience from his previous role as a partner at MNP, where he focused on publicly traded companies in innovative sectors.
The Board of PharmAla Biotech extends its gratitude to Mr. Carmelo Marelli, the outgoing CFO, for his dedicated service over the years.
Source: pharmala.ca
